Document Detail

Effect of almitrine administration on pulmonary arterial pressure in resting and exercising dogs.
MedLine Citation:
PMID:  2125354     Owner:  NLM     Status:  MEDLINE    
In addition to its well-known ventilatory effect, a small rise in pulmonary arterial pressure or pulmonary vascular resistance is occasionally observed with chronic administration of almitrine. In order to test the hypothesis of enhancement of exercise pulmonary vasoconstriction by almitrine, mongrel dogs were studied at rest and during submaximal exercise before and after 4 weeks of chronic ingestion of almitrine (10 mg/kg). It was shown that resting pulmonary arterial pressure (PAP) remained unchanged by almitrine treatment. However, when exercise was superimposed on almitrine medication, PAP was significantly increased throughout the exercise bout. Thus, the rise in PAP during the 20th min of exercise averaged 8.7 +/- 3.4 mm Hg after almitrine treatment while PAP increased by only 1.3 +/- 1.7 mm Hg before medication. The exaggerated exercise-induced PAP response in conjunction with the enhanced secretion of norepinephrine that we observed during almitrine treatment suggests that catecholamine could be involved in the pulmonary haemodynamic adjustments. Furthermore, mixed-venous PO2 (PvO2) both during rest and exercise declined with the prolongation of almitrine ingestion, suggesting that PvO2 might possibly be implicated in the pulmonary haemodynamic response to almitrine, in the same way as it is involved in the hypoxia-induced pulmonary vasoconstriction. These findings demonstrate that almitrine medication, even at a high dose, does not have any deleterious effect on pulmonary vasculature in resting conditions, but prolonged submaximal exercise should be proscribed in patients on a long-term therapy.
R J Favier; D Desplanches; R Pagliari; B Semporé; M H Mayet; B Simi; J M Péquignot; J Frutoso; R Flandrois
Related Documents :
6426354 - Oxygen saturation during exercise in cystic fibrosis.
1008344 - Five- to seven-year course of pulmonary function in cystic fibrosis.
5387024 - Mechanism of stimulation of type j pulmonary receptors.
8894334 - Lack of effect of delta f508 mutation on aerobic capacity in patients with cystic fibro...
10494774 - Regular exercise, plasminogen activator inhibitor-1 (pai-1) activity and the 4g/5g prom...
16395464 - Road pavers' occupational exposure to asphalt containing waste plastic and tall oil pitch.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Respiration physiology     Volume:  82     ISSN:  0034-5687     ISO Abbreviation:  Respir Physiol     Publication Date:  1990 Oct 
Date Detail:
Created Date:  1991-02-19     Completed Date:  1991-02-19     Revised Date:  2009-11-11    
Medline Journal Info:
Nlm Unique ID:  0047142     Medline TA:  Respir Physiol     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  75-87     Citation Subset:  IM; S    
URA 1341, Faculté de Médecine, Lyon, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Almitrine / pharmacology*
Blood Pressure / drug effects*,  physiology
Carbon Dioxide / blood
Epinephrine / blood
Norepinephrine / blood
Oxygen / blood
Physical Exertion
Pulmonary Artery / drug effects,  physiology
Pulmonary Circulation / drug effects*,  physiology
Reg. No./Substance:
124-38-9/Carbon Dioxide; 27469-53-0/Almitrine; 51-41-2/Norepinephrine; 51-43-4/Epinephrine; 7782-44-7/Oxygen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Isolation and characterization of human thyrotropin-releasing hormone (TRH) from an endocrine pancre...
Next Document:  Hereditary lysosomal diseases in Mexico. II. Laboratory diagnosis of mucopolysaccharidosis and mucol...